Loading clinical trials...
Loading clinical trials...
Outcomes of First-line Olaparib Combined With Bevacizumab Maintenance Therapy in Newly Diagnosed Ovarian Cancer Patients With tBRCA Wild-type Tumors: a Real-world Study
Conditions
Interventions
olaparib plus bevacizumab maintenance therapy
Start Date
June 1, 2022
Primary Completion Date
September 1, 2022
Completion Date
December 1, 2022
Last Updated
July 1, 2022
NCT07213804
NCT06051695
NCT06885697
NCT07035587
NCT01789229
NCT02869568
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions